Qualls D, Noy A, Straus D, Matasar M, et al. Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study. Leuk Lymphoma 2023 Jan 15:1-4. doi: 10.1080/10428194.2022.2164194.
PMID: 36642966